Stephens Inc. AR Boosts Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Stephens Inc. AR grew its holdings in Bristol-Myers Squibb (NYSE:BMY) by 7.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 167,394 shares of the biopharmaceutical company’s stock after acquiring an additional 12,085 shares during the quarter. Stephens Inc. AR’s holdings in Bristol-Myers Squibb were worth $9,468,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. AMF Tjanstepension AB lifted its position in shares of Bristol-Myers Squibb by 6.9% during the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock worth $31,618,000 after buying an additional 39,419 shares during the last quarter. Wedmont Private Capital grew its position in shares of Bristol-Myers Squibb by 14.1% in the 3rd quarter. Wedmont Private Capital now owns 8,095 shares of the biopharmaceutical company’s stock valued at $433,000 after buying an additional 999 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its stake in Bristol-Myers Squibb by 383.0% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 17,232 shares of the biopharmaceutical company’s stock worth $892,000 after acquiring an additional 13,664 shares in the last quarter. Valeo Financial Advisors LLC boosted its stake in Bristol-Myers Squibb by 6.2% in the third quarter. Valeo Financial Advisors LLC now owns 49,733 shares of the biopharmaceutical company’s stock valued at $2,573,000 after acquiring an additional 2,925 shares in the last quarter. Finally, Ritholtz Wealth Management grew its holdings in shares of Bristol-Myers Squibb by 81.0% during the third quarter. Ritholtz Wealth Management now owns 23,843 shares of the biopharmaceutical company’s stock worth $1,234,000 after purchasing an additional 10,669 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 0.8 %

NYSE:BMY opened at $56.96 on Monday. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.10. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The stock has a fifty day moving average price of $57.56 and a two-hundred day moving average price of $53.83. The stock has a market capitalization of $115.51 billion, a price-to-earnings ratio of -12.89, a PEG ratio of 2.13 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.81%. As a group, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.75 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were issued a $0.62 dividend. The ex-dividend date was Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.35%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio is currently -56.11%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BMY shares. Sanford C. Bernstein initiated coverage on Bristol-Myers Squibb in a report on Thursday, October 17th. They issued a “market perform” rating and a $56.00 target price for the company. Cantor Fitzgerald increased their price objective on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Leerink Partners raised shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $55.00 to $73.00 in a report on Tuesday, November 12th. Truist Financial increased their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, Bank of America restated a “neutral” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.